Versor Investments LP Takes $47.04 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Versor Investments LP Takes $47.04 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Versor Investments LP bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 625,067 shares of the company's stock, valued at approximately $47,036,000. Turning Point Therapeutics accounts for 1.8% of Versor Investments LP's portfolio, making the stock its 20th biggest position. Versor Investments LP owned 1.26% of Turning Point Therapeutics as of its most recent SEC filing.
Versor Investments LP在向美国证券交易委员会(SEC)提交的最新13F表格中表示,该公司在第二季度收购了Turning Point Therapeutics, Inc.(纳斯达克股票代码:TPTX——获取评级)的新股份。该基金购买了该公司625,067股股票,价值约47,036,000美元。Turning Point Therapeutics占Versor Investments LP投资组合的1.8%,使该股成为其第20大截至美国证券交易委员会最近提交文件,Versor Investments LP拥有Turning Point Therapeutics
Other institutional investors also recently modified their holdings of the company. State Street Corp raised its stake in Turning Point Therapeutics by 37.2% in the first quarter. State Street Corp now owns 3,119,926 shares of the company's stock valued at $83,770,000 after purchasing an additional 845,408 shares in the last quarter. Federated Hermes Inc. raised its stake in Turning Point Therapeutics by 19.7% in the first quarter. Federated Hermes Inc. now owns 2,075,037 shares of the company's stock valued at $55,715,000 after purchasing an additional 341,455 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in Turning Point Therapeutics by 69.1% in the second quarter. Frontier Capital Management Co. LLC now owns 195,959 shares of the company's stock valued at $14,746,000 after purchasing an additional 80,062 shares in the last quarter. Barclays PLC raised its stake in Turning Point Therapeutics by 352.3% in the fourth quarter. Barclays PLC now owns 92,085 shares of the company's stock valued at $4,393,000 after purchasing an additional 71,727 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Turning Point Therapeutics by 20.4% during the first quarter. JPMorgan Chase & Co. now owns 384,426 shares of the company's stock worth $10,323,000 after acquiring an additional 65,212 shares in the last quarter. Institutional investors own 90.33% of the company's stock.
其他机构投资者最近也修改了他们对该公司的持股。State Street Corp在第一季度将其在Turning Point Therapeutics的股份增加了37.2%。State Street Corp在上个季度又购买了845,408股股票后,现在拥有该公司3,119,926股股票,价值83,77万美元。联邦爱马仕公司在第一季度将其在Turning Point Therapeutics的股份提高了19.7%。联邦爱马仕公司在上个季度又购买了341,455股股票后,现在拥有该公司股票的2,075,037股,价值55,71.5万美元。前沿资本管理有限公司有限责任公司在第二季度将其在Turning Point Therapeutics的股份提高了69.1%。前沿资本管理有限公司有限责任公司在上个季度又购买了80,062股股票后,现在拥有该公司195,959股股票,价值14,746,000美元。巴克莱集团在第四季度将其在Turning Point Therapeutics的股份提高了352.3%。巴克莱集团在上个季度又购买了71,727股股票后,现在拥有该公司92,085股股票,价值43.93万美元。最后,摩根大通在第一季度将其在Turning Point Therapeutics的股份提高了20.4%。摩根大通在上个季度又收购了65,212股股票后,现在拥有该公司384,426股股票,价值10,323,000美元。机构投资者拥有该公司90.33%的股票。
Insider Activity at Turning Point Therapeutics
Turning Point Therapeu
In related news, CFO Paolo Tombesi sold 1,183 shares of the company's stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total value of $88,654.02. Following the sale, the chief financial officer now directly owns 28,700 shares in the company, valued at $2,150,778. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by company insiders.
在相关新闻中,首席财务官保罗·汤贝西在7月27日星期三进行的一笔交易中出售了该公司1,183股股票。该股票的平均售价为74.94美元,总价值为88,654.02美元。出售后,首席财务官现在直接拥有该公司28,700股股票,价值2,150,778美元。此次出售是在向美国证券交易委员会提交的一份文件中披露的,该文件可通过以下方式查阅 这个超链接. 8.60% 的股票目前由公司内部人士持有。
Wall Street Analysts Forecast Growth
华尔街分析师预测增长
Turning Point Therapeutics Price Performance
转折点疗法的价格表现
Shares of NASDAQ:TPTX remained flat at $76.01 during midday trading on Friday. The stock had a trading volume of 4,322 shares, compared to its average volume of 1,137,726. The firm has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. The business's 50 day simple moving average is $75.81 and its 200-day simple moving average is $59.18. Turning Point Therapeutics, Inc. has a 52 week low of $23.77 and a 52 week high of $82.20.
在周五午盘交易中,纳斯达克股票代码:TPTX的股价持平至76.01美元。该股的交易量为4,322股,而平均成交量为1,137,726股。该公司的市值为38.1亿美元,市盈率为-11.02,beta值为-0.18。该公司的50天简单移动平均线为75.81美元,其200天简单移动平均线为59.18美元。Turning Point Therapeutics, Inc. 创下52周低点23.77美元,创52周高点82.20美元。
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last released its quarterly earnings results on Monday, August 8th. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.78) by ($0.70). The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $2.27 million. The company's revenue was down 97.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.14) EPS. Research analysts forecast that Turning Point Therapeutics, Inc. will post -7.69 earnings per share for the current fiscal year.
Turning Point Therapeutics(纳斯达克股票代码:TPTX — 获取评级)最后一次发布季度财报是在8月8日星期一。该公司公布的本季度每股收益(2.48美元),比市场普遍预期的(1.78美元)低了(0.70美元)。该公司在本季度的收入为12万美元,而市场普遍估计为227万美元。该公司的收入同比下降了97.7%。去年同期,该公司公布了每股收益(1.14美元)。研究分析师预测,Turning Point Therapeutics, Inc.将在本财年公布每股收益-7.69美元。
Turning Point Therapeutics Profile
转折点疗法简介
(Get Rating)
(获取评分)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point Therapeutics, Inc是一家临床阶段的精准肿瘤生物制药公司,致力于设计和开发针对癌症遗传驱动因素的疗法。它开发了一系列酪氨酸激酶抑制剂 (TKI),用于靶向 TKI-naive 和 TKI 预治疗患者的癌症遗传驱动因素。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- 2 Regional Banks With Sector-Beating Price Performance
- MarketBeat: Week in Review 10/3-10/7
- ConAgra Brands Is A Value Pick For Income Investors
- 3 Stocks With Market-Beating Price Performance
- Lucid Motors May Test Investors' Resolve, But Should They Sell?
- 免费获取 StockNews.com 关于 Turning Point Therapeutics(TPTX)的研究报告的副本
- 2 家价格表现优于行业的区域性银行
- MarketBeat:本周回顾 10/3-10/7
- 康纳格拉品牌是收益投资者的超值选择
- 3 只价格表现优于市场的股票
- Lucid Motors 可能会考验投资者的决心,但他们应该卖出吗?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日转折点治疗的新闻和收视率 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Turning Point Therapeutics及相关公司最新新闻和分析师评级的简明每日摘要。